117 related articles for article (PubMed ID: 18073162)
1. Generation of resistant mutants of Mycobacterium chelonae and Mycobacterium fortuitum after exposure to subinhibitory concentrations of clarithromycin and moxifloxacin.
Rodriguez JC; Garcia-Pachon E; Flores E; Escribano I; Ruiz M; Royo G
J Chemother; 2007 Oct; 19(5):599-601. PubMed ID: 18073162
[No Abstract] [Full Text] [Related]
2. Topical antibacterial therapy for mycobacterial keratitis: potential for surgical prophylaxis and treatment.
Abshire R; Cockrum P; Crider J; Schlech B
Clin Ther; 2004 Feb; 26(2):191-6. PubMed ID: 15038942
[TBL] [Abstract][Full Text] [Related]
3. Mycobacterium chelonae infection in a tattoo site.
Preda VA; Maley M; Sullivan JR
Med J Aust; 2009 Mar; 190(5):278-9. PubMed ID: 19296796
[No Abstract] [Full Text] [Related]
4. High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan.
Yang SC; Hsueh PR; Lai HC; Teng LJ; Huang LM; Chen JM; Wang SK; Shie DC; Ho SW; Luh KT
Antimicrob Agents Chemother; 2003 Jun; 47(6):1958-62. PubMed ID: 12760874
[TBL] [Abstract][Full Text] [Related]
5. In vitro bactericidal activity of antibiotic combinations against clinical isolates of Mycobacterium chelonae.
Cremades R; Santos A; Rodríguez JC; Garcia-Pachon E; Ruiz M; Royo G
J Chemother; 2008 Feb; 20(1):43-7. PubMed ID: 18343742
[TBL] [Abstract][Full Text] [Related]
6. Fourth-generation fluoroquinolone-resistant mycobacterial keratitis after laser in situ keratomileusis.
Moshirfar M; Meyer JJ; Espandar L
J Cataract Refract Surg; 2007 Nov; 33(11):1978-81. PubMed ID: 17964409
[TBL] [Abstract][Full Text] [Related]
7. Antibiotic susceptibility pattern of rapidly growing mycobacteria.
Gayathri R; Therese KL; Deepa P; Mangai S; Madhavan HN
J Postgrad Med; 2010; 56(2):76-8. PubMed ID: 20622384
[TBL] [Abstract][Full Text] [Related]
8. Effect of subinhibitory concentrations of ciprofloxacin on Mycobacterium fortuitum mutation rates.
Gillespie SH; Basu S; Dickens AL; O'Sullivan DM; McHugh TD
J Antimicrob Chemother; 2005 Aug; 56(2):344-8. PubMed ID: 15956099
[TBL] [Abstract][Full Text] [Related]
9. In vitro antibiotic susceptibility of rapidly growing nontuberculous mycobacteria isolated from patients with microbial keratitis.
Reddy AK; Garg P; Babu KH; Gopinathan U; Sharma S
Curr Eye Res; 2010 Mar; 35(3):225-9. PubMed ID: 20373881
[TBL] [Abstract][Full Text] [Related]
10. Activity of various drugs alone or in combination against Mycobacterium fortuitum.
Santos A; Cremades R; Rodríguez JC; Garcia-Pachon E; Ruiz M; Royo G
J Infect Chemother; 2010 Feb; 16(1):64-7. PubMed ID: 20063030
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.
Disratthakit A; Doi N
Antimicrob Agents Chemother; 2010 Jun; 54(6):2684-6. PubMed ID: 20368403
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the bactericidal activity of quinolone antibiotics in a Mycobacterium fortuitum model.
Gillespie SH; Morrissey I; Everett D
J Med Microbiol; 2001 Jun; 50(6):565-570. PubMed ID: 11393294
[TBL] [Abstract][Full Text] [Related]
13. Screening for sterilizing activity of antibiotic combinations in an acid model of rapidly growing mycobacteria during the stationary phase of growth.
Cremades R; Santos A; Rodríguez JC; García-Pachón E; Ruiz M; Escribano I; Royo G
Chemotherapy; 2009; 55(2):114-8. PubMed ID: 19155619
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of cutaneous infections due to Mycobacterium fortuitum: two cases].
Régnier S; Martinez V; Veziris N; Bonvallot T; Meningaud JP; Caumes E
Ann Dermatol Venereol; 2008; 135(8-9):591-5. PubMed ID: 18789296
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of Mycobacterium massiliense lung disease with oral antibiotics only.
Koh WJ; Jeon K; Shin SJ
Antimicrob Agents Chemother; 2013 Feb; 57(2):1098-100. PubMed ID: 23183432
[No Abstract] [Full Text] [Related]
16. Clarithromycin and amikacin vs. clarithromycin and moxifloxacin for the treatment of post-acupuncture cutaneous infections due to Mycobacterium abscessus: a prospective observational study.
Choi WS; Kim MJ; Park DW; Son SW; Yoon YK; Song T; Bae SM; Sohn JW; Cheong HJ; Kim MJ
Clin Microbiol Infect; 2011 Jul; 17(7):1084-90. PubMed ID: 20946409
[TBL] [Abstract][Full Text] [Related]
17. [Susceptibility to antimicrobial agents of rapidly growing mycobacteria].
Ruiz-Aragón J; García-Agudo L; Flores S; Rodríguez MJ; Marín P; García-Martos P
Rev Esp Quimioter; 2007 Dec; 20(4):429-32. PubMed ID: 18563216
[TBL] [Abstract][Full Text] [Related]
18. Species Distribution and Macrolide Susceptibility of
Kim SY; Moon SM; Jhun BW; Kwon OJ; Huh HJ; Lee NY; Lee SH; Shin SJ; Kasperbauer SH; Huitt GA; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30885902
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial Susceptibility Testing and Molecular Characterization of Mycobacterium fortuitum Isolates in China.
Zheng HW; Pang Y; He GX; Song YY; Zhao YL
Biomed Environ Sci; 2017 May; 30(5):376-379. PubMed ID: 28549494
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of fluoroquinolones against Mycobacterium abscessus in vivo.
Caballero AR; Marquart ME; O'Callaghan RJ; Thibodeaux BA; Johnston KH; Dajcs JJ
Curr Eye Res; 2006 Jan; 31(1):23-9. PubMed ID: 16421016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
